MPP-Home

en / fr

The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.

New WHO hepatitis C treatment guidelines

The MPP welcomes the new global guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection published by the World Health Organization.

The Medicines Patent Pool Presents New Five-Year Strategy For Improving Access To Priority Treatments In Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines

Exploring The Expansion Of The Medicines Patent Pool’s Mandate To Patented Essential Medicines

A Feasibility Study Of The Public Health Needs And Potential Impact

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on our website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Projections

Projections Tool

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

17 million patient-years through MPP’s generic partners from January 2012 to December 2017

24 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

130+

130+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

553

553 million dollars saved, from January 2012 to December 2017

Latest News

12 November 2018

The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

Important collaboration will ensure affordable hepatitis C treatment options in low- and middle-income countries. San Francisco, 12 November 2018 – The Medicines Patent Pool (MPP) has today announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for people living with chronic hepatitis C (HCV). The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in 99 low- and middle-income countries (LMICs) and territories at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens. The agreement was launched at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2018 in San Francisco. “G/P is a priority therapy for licensing for the MPP, so this agreement with AbbVie is very good news for public health,” said Dr Marie-Paule Kieny, Chair of the MPP Governance Board. “It is a really import...

08 November 2018

The Medicines Patent Pool and Medicines For All Institute sign Memorandum of Understanding

In September 2018, the Medicines Patent Pool (MPP) and the Medicines For All Institute (M4ALL) signed a Memorandum of Understanding (MOU) that will ultimately accelerate access to global health medicines in low- and middle-income countries (LMICs), by promoting the reduced cost of active pharmaceutical ingredients (APIs) - a major cost driver in treating infectious diseases in the developing world. While there is a critical need for novel, cost-saving approaches to API production, neither innovator drug companies or generic manufacturers have the economic incentives to develop them. M4ALL (which operates under the auspices of the Virginia Commonwealth University School of Engineering) meets this need by identifying manufacturing routes that utilise the lowest-cost materials and most efficient tools available, which reduces the overall costs and the prices of essential medications, while preserving manufacturer margins and the security of supply. Access the MOU here About the Medicines Patent Pool...

03 October 2018

The Medicines Patent Pool and ViiV Healthcare sign extension of HIV licence agreement for dolutegravir to include Mongolia and Tunisia

Geneva, 3 October 2018. The Medicines Patent Pool (MPP) and ViiV Healthcare - a global specialist company - signed an extension of their licensing agreement in July 2018, to further increase access to key antiretroviral dolutegravir (DTG) for adults living with HIV in Mongolia and Tunisia. This amendment allows generic manufacturers to supply low-cost quality-assured DTG and combinations in the two countries. DTG-based regimens have been recommended by the World Health Organization as the preferred first-line treatment for people living with HIV, including adults and adolescents as well as children for whom there is approved DTG dosing. Notably, TLD (tenofovir disoproxil fumarate/lamivudine/dolutegravir) is a new convenient once-daily single-tablet regimen for adults and adolescents. DTG is also an important option in other lines of therapies. “The MPP has worked with long-standing partner ViiV Healthcare since 2014, when the initial licensing agreement was signed. But that was just a starting point”,...

Videos

Unable to load video, please allow cookie

Endorsements

“Central to our vision at AbbVie is developing therapies, such as our pan-genotypic HCV treatment, for the most serious diseases and providing access to those treatments. We are pleased to have reached today’s agreement [Licence agree...”

Unable to load twitter timeline, please allow cookie